As hypoxia and nutrient stress are known to upregulate GLUT expression on the cancer cell surface and given that GLUTs confer the tumor selectivity of Glu-MTX, the results of our study confirm the viability of the strategy to combat tumor microenvironment-induced drug resistance in solid malignancies through linking of anticancer compounds with glucose. The gene discussed is SLC2A1; the disease is cancer.